Natera Inc (NTRA)vsThermo Fisher Scientific Inc (TMO)
NTRA
Natera Inc
$369.39
+0.84%
HEALTHCARE · Cap: $46.72B
TMO
Thermo Fisher Scientific Inc
$651.45
-1.04%
HEALTHCARE · Cap: $225.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 1612% more annual revenue ($46.34B vs $2.71B). TMO leads profitability with a 15.0% profit margin vs -7.1%. TMO earns a higher WallStSmart Score of 60/100 (C+).
NTRA
Avoid31
out of 100
Grade: F
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NTRA.
Margin of Safety
-88.3%
Fair Value
$345.90
Current Price
$651.45
$305.55 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37.7% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
0.0% earnings growth
Weak financial health signals
Trading at 29.1x book value
ROE of -10.6% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
NTRA profiles as a hypergrowth stock while TMO is a value play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.53 — expect wider price swings.
NTRA is growing revenue faster at 37.7% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
TMO scores higher overall (60/100 vs 31/100) and 10.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?